Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × TTI-621 × Clear all

NCT05507541 2025-08-29

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse